Ex­ci­sion Bio­Ther­a­peu­tics’ at­tempt to gene ed­it HIV dis­ap­points. The com­pa­ny will now re­vamp vec­tor: #AS­GCT24

BAL­TI­MORE — HIV pa­tients who re­ceived a CRISPR-based gene edit­ing treat­ment de­vel­oped by Ex­ci­sion Bio­Ther­a­peu­tics saw the virus re­bound, and now the com­pa­ny is go­ing back …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.